Perspective Therapeutics to Present Updated VMT-α-NET Data at ESMO Congress 2026 — Perspective Therapeutics, Inc.

Event summary

Updated data on Perspective Therapeutics' [212Pb]VMT-α-NET program accepted for oral presentation at ESMO Congress 2026.
Presentation scheduled for October 23, 2026, in Madrid, Spain, with detailed abstract release planned for October 19, 2026.
Data includes cohort-level safety and efficacy results for advanced somatostatin receptor subtype 2 (SSTR2+)-expressing neuroendocrine tumors (NETs).
Interim clinical data from the study was previously presented at ASCO Annual Meeting in May 2026.

The big picture

Perspective Therapeutics' presentation at ESMO Congress 2026 underscores the growing importance of targeted alpha-therapies in oncology. The company's focus on somatostatin receptor subtype 2 (SSTR2) expressing tumors aligns with broader industry trends toward precision medicine and theranostic approaches, which combine diagnostic imaging with targeted therapy to improve patient outcomes.

What we're watching

Clinical Efficacy: How the updated data from Cohorts 1–3 will impact the perceived efficacy and safety profile of [212Pb]VMT-α-NET.
Regulatory Pathway: Whether the positive data presentation at ESMO will accelerate regulatory discussions or future trial designs.
Competitive Positioning: The pace at which Perspective Therapeutics can differentiate its theranostic approach in the crowded radiopharmaceutical space.